Kevin Esch

Executive Vice President and President, Research and Development · Zoetis

Animal Health

Kevin Esch leads Zoetis’ research and development organization after a veterinary practice career and leadership of its global therapeutics portfolio.

Last reviewed: Nov 2, 2026

Kevin Esch

Executive Vice President and President, Research and Development
Zoetis

Last Reviewed: November 2, 2026

Executive Summary

Kevin Esch leads Zoetis’ research and development organization after a veterinary practice career and leadership of its global therapeutics portfolio.

Career Highlights

  • Became president of research and development on January 1, 2026.
  • Joined Zoetis in 2014 after more than a decade in veterinary practice.
  • Helped integrate the Petmedix and Adivo acquisitions.

Professional Journey

Esch began his career as a practicing veterinarian and veterinary practice owner, spending more than a decade in clinical work before entering industry. His subsequent training and research combined veterinary medicine, public health, immunobiology and anatomic pathology.

He joined Zoetis in 2014 and progressed through its research and development organization, including appointments as executive director of research and vice president of global therapeutics. From May through December 2025, as senior vice president of global therapeutics, he led pharmaceutical and biopharmaceutical development from discovery and molecule design through pharmacology, safety assessment and clinical development. He also helped integrate Petmedix and Adivo, acquisitions that extended the company’s antibody development capabilities.

Ahead of assuming the top R&D role, Esch presented the therapeutics portfolio at Zoetis’ December 2025 innovation webcast. He explained its chronic kidney disease programs, which combined diagnostics and potential treatments intended to identify disease earlier and slow its progression. He also discussed experimental oncology programs targeting canine lymphoma and melanoma.

On January 1, 2026, he succeeded Rob Polzer as executive vice president and president of research and development. He now leads the global organization developing medicines, vaccines, diagnostics and technologies for companion animals and livestock.

Esch also chairs the external research advisory board at The Ohio State University College of Veterinary Medicine. His professional service has included treasurer and chief financial officer responsibilities on the American College of Veterinary Pathologists board.